BRCA-deficient and triple negative breast cancers: Is olaparib effective in both subtypes?

Journal of B.U.ON.

Volumn 16, Issue 1, 2011, Pages 184-185

  Sahin, I ^a   Ararat, E ^a   Altundag, Kadri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; KI 67 ANTIGEN; OLAPARIB; PROTEIN P53;

BRCA DEFICIENT BREAST CANCER; BREAST CANCER; GENE MUTATION; GENETIC TRANSCRIPTION; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; LETTER; PHENOTYPE; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; HUMANS; MUTATION; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 79954476343     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-244.
2. Kandel MJ, Stadler Z, Masciari S et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol 2006;24(18 Suppl): (abstr 508).
3. Couch FJ. Genetic epidemiology of BRCAl. Cancer Biol Ther 2006;3:509-514.
4. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423. (Pubitemid 36842560)
5. Turner NC, Reis-Filho JS, Russell AM et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-2132. (Pubitemid 46514749)